Table 2.
Mean values ± SD of all the investigated parameters in the study based on the NAFLD group
|
Parameter (mean value ± SD) |
Grade 0 |
Grade I |
Grade II |
|
|
Age [years] |
T |
59±6.2 |
45.7±8.57 |
56.06±9.85 |
|
M |
57.33±3.21 |
46.58±9.6 |
52.9±10.08 |
|
|
W |
61.5±10.6 |
43.6±5.68 |
61.33±7.42 |
|
|
FF indicated by liver biopsy [%] |
T |
3±1 |
22.88±7.12 |
48.93±10.25 |
|
M |
3±1 |
22.25±6.86 |
45.5±10.27 |
|
|
W |
3±1.41 |
24.4±8.32 |
54.66±7.89 |
|
|
FF indicated by liver MRS [%] |
T |
3.6±0.54 |
23±6.95 |
49.93±9.58 |
|
M |
3.33±0.57 |
22.41±6.84 |
46.8±9.87 |
|
|
W |
4±0 |
24.4±7.82 |
55.16±6.88 |
|
|
Serum triglycerides [mg/dL] |
T |
155.2±3.96 |
210.47±43.09 |
296.37±29.72 |
|
M |
152.66±2.51 |
210.41±48.23 |
286.5±27.8 |
|
|
W |
159±1.41 |
210.6±32.08 |
312.83±27.17 |
|
|
Total serum cholesterol [mg/dL] |
T |
265.8±29.54 |
255.35±75.57 |
252.37±60.23 |
|
M |
257.33±38.42 |
242.91±65.76 |
266.5±61.47 |
|
|
W |
278.5±0.7 |
285.2±96.81 |
228.83±54.95 |
|
|
Serum ALT [U/L] |
T |
31.6±2.6 |
49.05±15.38 |
50.12±18.51 |
|
M |
32.66±2.3 |
46.91±15.35 |
50.9±19.73 |
|
|
W |
30±2.82 |
54.2±15.84 |
48.83±17.98 |
|
|
Serum AST [U/L] |
T |
29±2.34 |
41.47±11.97 |
42.81±15.62 |
|
M |
30.33±2.08 |
39.25±11.74 |
43.9±15.84 |
|
|
W |
27±0 |
46.8±12 |
41±16.56 |
|
|
Serum glucose [mg/dL] |
T |
99.6±3.04 |
111.41±36.23 |
131.62±35.15 |
|
M |
98.66±3.78 |
116.25±39.43 |
131.3±35.16 |
|
|
W |
101±1.41 |
99.8±27.1 |
132.16±38.49 |
|
|
BMI [kg/m2] |
T |
25.2±2.38 |
32±4.96 |
35.5±4.83 |
|
M |
26.33±2.51 |
31.58±4.83 |
35±5.53 |
|
|
W |
23.5±0.7 |
33±5.7 |
36.33±3.66 |
|
SD: Standard deviation; NAFLD: Non-alcoholic fatty liver disease; FF: Fat fraction; MRS: Magnetic resonance spectroscopy; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; T: Total (men and women); M: Men; W: Women